Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. 2017

Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
Institut Cochin, Paris, France.

Myelodysplastic syndromes (MDSs) are hematopoietic stem cell disorders in which recurrent mutations define clonal hematopoiesis. The origin of the phenotypic diversity of non-del(5q) MDS remains unclear. Here, we investigated the clonal architecture of the CD34+CD38- hematopoietic stem/progenitor cell (HSPC) compartment and interrogated dominant clones for MDS-initiating cells. We found that clones mainly accumulate mutations in a linear succession with retention of a dominant subclone. The clone detected in the long-term culture-initiating cell compartment that reconstitutes short-term human hematopoiesis in xenotransplantation models is usually the dominant clone, which gives rise to the myeloid and to a lesser extent to the lymphoid lineage. The pattern of mutations may differ between common myeloid progenitors (CMPs), granulomonocytic progenitors (GMPs), and megakaryocytic-erythroid progenitors (MEPs). Rare STAG2 mutations can amplify at the level of GMPs, from which it may drive the transformation to acute myeloid leukemia. We report that major truncating BCOR gene mutation affecting HSPC and CMP was beneath the threshold of detection in GMP or MEP. Consistently, BCOR knock-down (KD) in normal CD34+ progenitors modifies their granulocytic and erythroid differentiation. Clonal architecture of the HSPC compartment and mutations selected during differentiation contribute to the phenotypic heterogeneity of MDS. Defining the hierarchy of driver mutations provides insights into the process of transformation and may guide the search for novel therapeutic strategies.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002895 Chromosomes, Human, Pair 5 One of the two pairs of human chromosomes in the group B class (CHROMOSOMES, HUMAN, 4-5). Chromosome 5
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell

Related Publications

Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
October 2012, Seminars in hematology,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
September 2000, Blood,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
March 2020, Expert review of hematology,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
January 2012, Blood,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
July 2017, Seminars in hematology,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
May 2020, International journal of molecular sciences,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
June 2024, European journal of haematology,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
March 2023, Cytometry. Part B, Clinical cytometry,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
May 2022, Experimental hematology & oncology,
Virginie Chesnais, and Marie-Laure Arcangeli, and Caroline Delette, and Alice Rousseau, and Hélène Guermouche, and Carine Lefevre, and Sabrina Bondu, and M'boyba Diop, and Meyling Cheok, and Nicolas Chapuis, and Laurence Legros, and Sophie Raynaud, and Lise Willems, and Didier Bouscary, and Evelyne Lauret, and Olivier A Bernard, and Olivier Kosmider, and Françoise Pflumio, and Michaela Fontenay
December 2023, The Malaysian journal of pathology,
Copied contents to your clipboard!